Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) Return on Equity (2023 - 2025)

Historic Return on Equity for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to 0.88%.

  • Immunome's Return on Equity rose 4800.0% to 0.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88%, marking a year-over-year increase of 4800.0%. This contributed to the annual value of 2.03% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Immunome's Return on Equity is 0.88%, which was up 4800.0% from 0.78% recorded in Q2 2025.
  • In the past 5 years, Immunome's Return on Equity ranged from a high of 0.78% in Q2 2025 and a low of 1.74% during Q4 2023
  • Its 3-year average for Return on Equity is 1.17%, with a median of 1.09% in 2024.
  • As far as peak fluctuations go, Immunome's Return on Equity surged by 1900bps in 2024, and later soared by 4800bps in 2025.
  • Quarter analysis of 3 years shows Immunome's Return on Equity stood at 1.74% in 2023, then grew by 11bps to 1.54% in 2024, then skyrocketed by 43bps to 0.88% in 2025.
  • Its Return on Equity was 0.88% in Q3 2025, compared to 0.78% in Q2 2025 and 0.89% in Q1 2025.